QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)

Novartis - NVS SEC Filings & 10K Form

$89.82
+0.26 (+0.29%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$89.46
$89.96
50-Day Range
$74.61
$89.82
52-Week Range
$74.09
$94.26
Volume
1.48 million shs
Average Volume
2.41 million shs
Market Capitalization
$198.74 billion
P/E Ratio
9.23
Dividend Yield
2.41%
Price Target
$85.45

Recent Novartis SEC Filings

DateFilerForm TypeView
10/25/2022
8:40 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/24/2022
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/21/2022
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/25/2022
7:58 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/19/2022
5:49 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/27/2022
3:38 PM
Novartis (Reporting)
NOVARTIS PHARMA AG (Reporting)
PRECISION BIOSCIENCES INC (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/31/2022
3:46 PM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
04/26/2022
3:46 PM
Novartis (Filer)
Form 20-F/A
04/26/2022
8:04 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2021
5:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/21/2021
5:55 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2021
5:03 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
04/27/2021
6:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/23/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/09/2021
8:18 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/05/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/29/2021
1:05 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/26/2021
7:59 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/26/2021
7:58 AM
Novartis (Filer)
Form IRANNOTICE
01/26/2021
7:56 AM
Novartis (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
12/21/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/24/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2020
4:23 PM
Novartis (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
10/27/2020
6:04 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/16/2020
7:34 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/23/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/20/2020
1:21 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/19/2020
3:31 PM
Novartis (Filed by)
XOMA Corp (Subject)
XOMA Corp (Subject)
XOMA Corp (Subject)
Form SC 13G/A
08/17/2020
1:15 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/14/2020
3:32 PM
Cellular Biomedicine Group, Inc. (Issuer)
Novartis (Reporting)
NOVARTIS PHARMA AG (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
07/21/2020
8:38 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/16/2020
3:53 PM
Novartis (Reporting)
NOVARTIS PHARMA AG (Reporting)
Poseida Therapeutics, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/13/2020
5:02 AM
Novartis (Reporting)
NOVARTIS PHARMA AG (Reporting)
Poseida Therapeutics, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/02/2020
6:44 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2020
6:15 PM
Akouos, Inc. (Issuer)
Akouos, Inc. (Issuer)
Novartis (Reporting)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/25/2020
2:17 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2020
8:16 PM
Forma Therapeutics Holdings, Inc., (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/17/2020
4:47 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2020
7:56 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2020
5:33 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2020
7:02 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2020
4:36 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2020
7:53 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
05/12/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2020
6:58 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/02/2020
6:50 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2020
9:15 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2020
9:15 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/19/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/28/2020
7:29 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/12/2020
2:34 PM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form 424B5
02/11/2020
6:57 AM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form 424B5
01/31/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2020
9:40 AM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form F-3ASR
01/29/2020
8:13 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/29/2020
8:07 AM
Novartis (Filer)
Form IRANNOTICE
01/29/2020
7:51 AM
Novartis (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
01/06/2020
5:29 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T/A
01/06/2020
5:10 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/23/2019
7:01 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T/A
12/19/2019
7:02 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T/A
12/16/2019
5:10 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/05/2019
6:58 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T
12/05/2019
5:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/25/2019
3:52 PM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-C
11/25/2019
6:32 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-C
11/25/2019
5:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/15/2019
4:03 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/12/2019
3:15 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2019
4:23 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/01/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/30/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2019
7:08 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/08/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/02/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2019
5:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/30/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/18/2019
8:41 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/01/2019
1:20 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/07/2019
6:21 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2019
9:00 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
05/30/2019
8:27 PM
BICYCLE THERAPEUTICS plc (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2019
1:35 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2019
1:23 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/22/2019
8:43 PM
BICYCLE THERAPEUTICS Ltd (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/09/2019
5:06 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2019
4:23 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2019
6:03 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2019
12:09 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2019
8:26 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2019
5:26 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/05/2019
4:14 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2019
7:23 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2019
7:09 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
This page (NYSE:NVS) was last updated on 12/1/2022 by MarketBeat.com Staff